Byczy
Pfizer's stock rises 1.3% to $25.13 amid FDA approval and analyst updates.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
Pfizer's stock price increased by 1.3% to $25.13 following the FDA's approval of a new bladder cancer treatment regimen and positive analyst assessments. The company also declared a quarterly dividend of $0.43 per share, yielding approximately 6.9%.
Kluczowe punkty
- FDA approves new bladder cancer regimen, expanding Pfizer's oncology portfolio.
- Analysts maintain 'Buy' ratings; Guggenheim sets price target at $35.
- Institutional investors adjust holdings; Sanctuary Advisors increases stake by 6.3%.
- Pfizer declares quarterly dividend of $0.43 per share, yielding 6.9%.
Źródła
- Pfizer (NYSE:PFE) Stock Price Up 1.3% - Here's WhyMarketBeat · July 16, 2026
- Guggenheim cuts Pfizer stock price target to $35 on model updateInvesting.com · July 13, 2026
- Pfizer Inc. $PFE Stock Holdings Boosted by Sanctuary Advisors LLCMarketBeat · July 16, 2026
- Pfizer Declares Third-Quarter 2025 DividendNasdaq · June 25, 2025
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
